Evidence map›Paper›PMID 41484518›Full record

ArticleInternational urology and nephrology2026

Nefecon in IgA nephropathy: real-world renal efficacy, safety profile, and treatment response from a 9-month retrospective cohort analysis.

Yanyan Zhang, Yingying Lin, Wei Wang, Guishen Li, Shasha Chen

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanyan Zhang *School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Yingying Lin *Department of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu, 610072, Sichuan, China.
Wei WangDepartment of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu, 610072, Sichuan, China.
Guishen LiDepartment of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu, 610072, Sichuan, China.
Shasha ChenDepartment of Nephrology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Sichuan Clinical Research Center for Kidney Diseases, University of Electronic Science and Technology of China, Chengdu, 610072, Sichuan, China. sasha.nju.edu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the real-world clinical efficacy and safety of Nefecon, a targeted-release formulation of budesonide, in patients with IgA nephropathy (IgAN).

methodsRetrospective cohort analysis of 40 biopsy-confirmed IgAN patients receiving Nefecon 16 mg/day. PRIMARY ENDPOINT: change in proteinuria at 9 months. Secondary endpoints: eGFR trajectory, remission rates, and safety.

resultsAt 9 months, proteinuria decreased from 2.24 ± 1.64 to 0.69 ± 0.59 g/day (60.2% reduction; p < 0.001), with 85% and 72.5% of patients achieving ≥ 30% and ≥ 50% reductions, respectively. Mean eGFR improved from 49.5 ± 22.6 to 53.6 ± 27.6 mL/min/1.73 m

conclusionIn real-world practice, Nefecon demonstrates significant efficacy in reducing proteinuria, improving renal function, and achieving high remission rates in IgAN patients over 9 months, with a favorable safety profile. Subgroup analyses highlight that baseline renal function, proteinuria severity, biopsy interval, and combination with immuno-suppressants may influence treatment response. Larger prospective studies are needed to validate these findings.

Indexed as

BudesonideGlomerulonephritis, IGAAdultFemaleGlomerular Filtration RateHumansMaleMiddle AgedProteinuriaRemission InductionRetrospective StudiesTreatment OutcomeBudesonideIgA nephropathy (immunoglobulin A nephropathy)Nefecon (targeted-release budesonide)Remission rateRetrospective cohort studySafetyTreatment response

Identifiers

PMID41484518

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.